سال انتشار: ۱۳۸۷

محل انتشار: دومین کنگره بین المللی علوم و فناوری نانو

تعداد صفحات: ۴

نویسنده(ها):

P EbrahimnejaD – Novel Drug Delivery Systems Lab, Faculty of Pharmacy, Tehran University of Medical Sciences
F Atyabi – Medical Nanotechnology Research Centre, Tehran University of Medical Sciences, Tehran
A Sajadi – Medical Research Centre, Faculty of Pharmacy, Mashhad University of Medical Sciences
F Movaghari – Research and Development Dept., Shahre-Daru Pharmaceutical Co., Tehran

چکیده:

SN-38 is an active metabolite of rinotecan, a derivative of camptothecin that is for the treatment of recurrent, metastatic colorectal cancer (1). However, the development of this drug has been largely hindered by the poor solubility and stability of SN-38 in pharmaceutically acceptable solvents (2). A novel and well-characterized PLGA nanoparticles based formulation of SN-38 was developed that would overcome the aforementioned problems. To support ongoing formulation development, a simple and reproducible analytical method was needed. The objective of this study was to develop a simple HPLC/UV method for determination of SN-38 in PLGA nanoparticles